Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Blastic plasmacytoid dendritic cell neoplasms: current and future treatment options

Naveen Pemmaraju • 15 May 2020
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, discusses novel treatments that have been developed against blastic plasmacytoid dendritic cell neoplasms (BPDCP), a rare and aggressive disease affecting skin, bone marrow and lymph nodes. Tagraxofusp, a CD123 targeted therapy has gained FDA approval for BPDCN as CD123 (encoding IL3RA) is often overexpressed in these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naveen Pemmaraju

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Novel agents and approaches being explored in second-line myelofibrosis
14:29
Novel agents and approaches being explored in second-line myelofibrosis
Claire Harrison et al. • 2 Oct 2026
Evolving treatment landscape in MF: JAK inhibitors, combination therapy, and novel agents
1:39
Evolving treatment landscape in MF: JAK inhibitors, combination therapy, and novel agents
Naveen Pemmaraju • 10 Sep 2026
Exploring JAK inhibitor-based combination strategies in myelofibrosis
1:55
Exploring JAK inhibitor-based combination strategies in myelofibrosis
Naveen Pemmaraju • 10 Sep 2026

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals